Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

Exclusion Criteria

• •1. Is currently participating or has participated in another interventional clinical study in the past 2 weeks;
• •2. Is age \<18 years old.
• •3. Has had known or previous hypersensitivity or allergic reactions to oral ivermectin before;
• •4. Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results;
• •5. Taking any medication known to interact with ivermectin like Dasabuvir (theoretical) or warfarin (probable).
• •6. Is planning a trip to a sunny climate, to use tanning booths or use other UV sources throughout the course of this study;
• •7. Has a history of hypersensitivity to any substance in investigational preparation;
• •8. Has any clinically significant medical condition or laboratory abnormality that would, in the opinion of the Investigator, put the patient at undue risk or interfere with the interpretation of the study results;
• •9. Is currently pregnant or breastfeeding.
• •10. Has other skin conditions that might interfere with Atopic Dermatitis diagnosis and/or evaluation (i.e. psoriasis current active viral, bacterial and fungal skin infections) as assessed by the Investigator;
• •11. Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation
• •12. History of congestive heart failure; cardiac arrhythmias; or other findings of ventricular dysfunction.
• •13. History of current evidence of malabsorption or liver disease.
• •14. Cannot read and speak English fluently.
• •15. Does not have at least 1% body surface area with lesional atopic dermatitis